The N=1 Collaborative Corporate Alliance provides a structured way for companies to engage in the evolving ecosystem of individualized genomic medicine. Rather than a traditional sponsorship model, the Alliance is designed for shared learning, collaboration, and meaningful participation across a complex and rapidly developing field.

Why the Corporate Alliance Exists

Advancing individualized therapies for ultra-rare conditions requires coordination across many stakeholders — including researchers, clinicians, patient communities, regulators, and industry.

The Corporate Alliance creates space for companies to:

• Engage directly with the broader ecosystem
• Contribute expertise and perspectives
• Better understand emerging challenges and opportunities
• Support the development of shared infrastructure

Through this model, companies are not positioned as sponsors of isolated initiatives, but as participants in a collaborative effort to move the field forward.

What Participation Looks Like

Corporate Alliance participants engage with N1C through opportunities such as:

• Participation in ecosystem-wide discussions and knowledge exchange
• Engagement with N1C seminars and community initiatives
• Insight into evolving practices and challenges in individualized medicine
• Collaboration with stakeholders across disciplines and institutions

The structure is intentionally flexible, allowing participation to evolve alongside the needs of the field.

Who Should Participate

The Corporate Alliance is designed for companies that are:

• Working in or adjacent to individualized or ultra-rare disease therapeutics
• Interested in engaging beyond traditional sponsorship or marketing models
• Committed to supporting responsible, patient-centered approaches
• Looking to better understand and contribute to the evolving ecosystem

This includes biotechnology and pharmaceutical companies, as well as organizations supporting research, development, and delivery of individualized therapies.

Supporting The Ecosystem

Participation in the Corporate Alliance helps support N1C’s broader mission, including:

• Convening stakeholders across the ecosystem
• Developing shared knowledge and practical resources
• Advancing coordination and visibility across individualized therapy efforts

This support enables N1C to continue building the infrastructure needed to move individualized medicine forward.